Macau Business23 分钟
Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib ...
SINTBILO® (tafolecimab injection), developed independently by Innovent, is a fully human lgG2 monoclonal antibody that can specifically bind to PCSK9, reducing LDL-C levels by inhibiting ...